Cite
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.
MLA
Xu, Qianqian, et al. “Combined BRAF and PIM1 Inhibitory Therapy for Papillary Thyroid Carcinoma Based on BRAFV600E Regulation of PIM1: Synergistic Effect and Metabolic Mechanisms.” Neoplasia, vol. 52, June 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.neo.2024.100996.
APA
Xu, Q., Wang, J., Mao, Y., Xuan, Z., Yang, K., Tang, X., & Zhu, X. (2024). Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms. Neoplasia, 52, N.PAG. https://doi.org/10.1016/j.neo.2024.100996
Chicago
Xu, Qianqian, Jiaqi Wang, Yuting Mao, Ziyang Xuan, Ke Yang, Xi Tang, and Xin Zhu. 2024. “Combined BRAF and PIM1 Inhibitory Therapy for Papillary Thyroid Carcinoma Based on BRAFV600E Regulation of PIM1: Synergistic Effect and Metabolic Mechanisms.” Neoplasia 52 (June): N.PAG. doi:10.1016/j.neo.2024.100996.